Deepika polineni.

The American Thoracic Society's Public Advisory Roundtable (PAR) is pleased to invite you to our . 17th annual FREE patient/family education dayTherapeutic beta-lactam dosages and broad-spectrum antibiotics are associated with reductions in microbial richness and diversity in persons with cystic fibrosis. Andrea Hahn. , Aszia Burrell ...KU Medical Center was one of the sites of a phase 3 trial that led to the approval of the drug, known by its brand name, Trikafta, by the U.S. Food and Drug Administration on October 21.KU Medical Center was one of the sites of a phase 3 trial that led to the approval of the drug, known by its brand name, Trikafta, by the U.S. Food and Drug Administration on October 21.The White Plague. Mohamad Badr Jandali, MD & Deepika Polineni, MD Kansas University Medical Center, Department of Pulmonary and critical care Medicine. Case. A 52-year-old male from Mexico with advanced alcoholic liver disease presented with confusion, cough, and mild hemoptysis.

Deepika Polineni, MD, MPH, will review past and current drug trials that are targeting the needs of people with CF via a multi-organ approach. Nicole Mayer Hamblett, PhD, will provide an overview of the comprehensive clinical trial strategy to enable novel therapeutics and optimal treatment regimens to quickly advance, furthering our mission of ...Aztreonam is a monobactam antibiotic with activity against Gram-negative aerobic bacteria including PA. Aztreonam exerts its anti-bacterial activity by binding to penicillin-binding protein-3 (PBP-3), inactivating it, resulting in the disruption of bacterial cell wall synthesis and ultimate cell death. 9,14-17 Aztreonam's monocylic beta-lactam structure results in resistance to hydrolysis ...Deepika Polineni, MD, MPH Assistant Professor Pulmonary, Critical Care and Sleep Medicine University of Kansas Medical Center Kansas City, KS Jane E. Gross, MD, PhD Assistant Professor, Department of Pediatrics and Medicine Divisions of Pediatric Pulmonary Medicine and Pulmonary, Critical Care and Sleep Medicine National Jewish Health Denver, CO

3:30 pm - 4:25 pm mRNA Therapies for Cystic Fibrosis - Deepika Polineni, MD, MPH 4:25 pm - 5:30 pm Exhibitor Hall/Lounge Activities 5:30 pm - 6:00 pm Buffet (In-Person) 6:00 pm - 7:15 pm CFRI Awards Celebration with Special Guests 7:30 pm - 9:30 pm Dance Party Sunday, July 30, 2023 (In Person and Virtual)

Peter G Middleton 1 , Marcus A Mall 1 , Pavel Dřevínek 1 , Larry C Lands 1 , Edward F McKone 1 , Deepika Polineni 1 , Bonnie W Ramsey 1 , Jennifer L Taylor-Cousar 1 , Elizabeth Tullis 1 , François Vermeulen 1 , Gautham Marigowda 1 , Charlotte M McKee 1 , Samuel M Moskowitz 1 , Nitin Nair 1 , Jessica Savage 1 , Christopher Simard 1 , Simon ...otypes. However, a significant proportion of the CF population is in need of alternative treatment strategies to address CFTR variants that are ineligible for therapeutic protein correction and/or potentiation. Current drug development efforts of nucleic-acid based therapies (i.e., DNA and RNA based therapies) in CF are informed by historic …All members of the Editorial Board have identified their affiliated institutions or organizations, along with the corresponding country or geographic region. Elsevier remains neutral with regard to any jurisdictional claims. Read the latest articles of CHEST at ScienceDirect.com, Elsevier's leading platform of peer-reviewed scholarly literature.Europe PMC is an archive of life sciences journal literature.

‪University of Kansas‬ - ‪‪Cited by 2,466‬‬ - ‪cystic fibrosis‬ - ‪lung inflammation‬ - ‪extracellular vesicles‬ - ‪primary ciliary dyskinesia‬

Overall, studies demonstrated that inhaled aztreonam is a safe and effective antimicrobial treatment for the eradication of newly acquired P. aeruginosa and long-term suppressive therapy of chronic endobronchial infection among people with cystic fibrosis. Keywords: Cystic fibrosis, aztreonam lysine, inhalation, Pseudomonas.

Deepika Polineni, MD, MPH, and Nicole Mayer-Hamblett, PhD Presented at the North American Cystic Fibrosis Conference (NACFC), November 4, 2022. Video. WORLDSYMPOSIUM 2022. An Open-label, Phase 1/2 Trial of Gene Therapy 4D-310 in Adult Males with Fabry Disease.n in CF. We evaluated whether therapy with the CFTR modulator combination lumacaftor/ivacaftor (luma/iva) has a beneficial impact on SIBO as measured by breath testing (BT). Methods: A multicenter longitudinal study of CFTR-dependent disease profiling (NCT02477319) included a prospective evaluation for SIBO by BT. Tidal breath samples were collected after fasting and 15, 30, 45, 60, 90, and ...METHODS. We conducted a phase 3, double-blind, randomized, active-controlled trial involving patients 12 years of age or older with cystic fibrosis and Phe508del -gating or Phe508del -residual function genotypes. After a 4-week run-in period with ivacaftor or tezacaftor-ivacaftor, patients were randomly assigned to receive elexacaftor ...Abstract. Patients with cystic fibrosis have increased risk of pulmonary infections, and reducing spread of microorganisms is critical. To improve hospital-staff adherence to infection control guidelines, we implemented brightly colored Safe Zone floor decals, staff compliance contracts, and an infection control in-service video.AMERICAN THORACIC SOCIETY DOCUMENTS Diagnosis of Primary Ciliary Dyskinesia An Official American Thoracic Society Clinical Practice Guideline Adam J. Shapiro, Stephanie D. Davis, Deepika Polineni, Michele Manion, Margaret Rosenfeld, Sharon D. Dell,Physician-scientists Gregory Gan and Deepika Polineni, who research cancer and cystic fibrosis, have teamed up to test a new drug with the potential to keep COVID-19 patients from needing a ventilator.Amik Sodhi, Katherine Cox-Flaherty, Meredith Kendall Greer, Tasnim I Lat, Yuqing Gao, Deepika Polineni, Margaret A Pisani, Ghada Bourjeily, Marilyn K Glassberg, Carolyn D'Ambrosio.

Yi-Hui ZHOU | Cited by 6,783 | of North Carolina State University, North Carolina (NCSU) | Read 114 publications | Contact Yi-Hui ZHOUDeepika Polineni; Christopher M Oermann; Patients with cystic fibrosis (CF) develop pulmonary disease secondary to airway infection and dysregulated inflammation. Therapeutic innovations such as ...Stimulation of inducible nitric oxide synthase in rat liver by hyaluronan fragments. Don C. Rockey, John J. Chung, Charlotte M. McKee, Paul W. Noble> ;Hepatology. 1998 Jan 1. 235 citations. Hyaluronan Fragments Induce Nitric-oxide Synthase in Murine Macrophages through a Nuclear Factor κB-dependent Mechanism *.The clinical phenotype of cystic fibrosis (CF), chronic infection, and inflammation leading to progressive obstructive lung disease and pancreatic insufficiency is caused by absence or dysfunction of the CFTR (cystic fibrosis transmembrane conductance regulator) protein ().Dr. Deepika Polineni, Assistant Professor of Medicine, The University of Kansas Hospital; Heather Hawthorne, Research Manager, Cystic Fibrosis Clinical Research Unit, University of Alabama at Birmingham;Dr. Carlos E. Milla is a Pediatric Pulmonologist in Palo Alto, CA. Find Dr. Milla's phone number, address, insurance information, hospital affiliations and more.Deepika Polineni, M.D. University of Kansas Medical Center. Kansas City, Kansas. ... Griese M, Costa S, Linnemann RW, Mall MA, McKone EF, Polineni D, et al. A phase 3, open-label extension study ...

NHLBI in planning collaboration with NIDDK, NIAID and the Cystic Fibrosis Foundation is hosting a virtual workshop in June to bring together experts in Cystic Fibrosis (CF) clinical-translational research to address critical questions and inform the field of the future research needs in the era of highly effective modulator therapies (HEMT) for the treatment of CF.Dr. Raksha Jain is a Pulmonologist in Dallas, TX. Find Dr. Jain's phone number, address, insurance information, hospital affiliations and more.

Deepika Polineni 1 , Stephanie D Davis 2 , Sharon D Dell 3 Affiliations 1 Division of Pulmonary and Critical Care Medicine, Department of Internal Medicine, University of Kansas School of Medicine, Kansas City, Kansas.The trial will be led by co-investigators Gregory Gan, M.D., Ph.D. and Deepika Polineni, M.D., M.P.H. The trial is a Phase 2a, randomized, double-blind, placebo-controlled trial to investigate the safety and efficacy of ATI-450, when used in addition to standard of care therapy.Deepika Polineni. Search for articles by this author, Michele Manion . x. Michele Manion. Search for articles by this author, Margaret Rosenfeld . x. ... Yilmaz O, Davis SD, Polineni D, et al. Accuracy of nasal nitric oxide measurement as a diagnostic test for primary ciliary dyskinesia: a systematic review and meta-analysis. Ann Am Thorac Soc ...AMERICAN THORACIC SOCIETY DOCUMENTS Diagnosis of Primary Ciliary Dyskinesia An Official American Thoracic Society Clinical Practice Guideline Adam J. Shapiro, Stephanie D. Davis, Deepika Polineni, Michele Manion, Margaret Rosenfeld, Sharon D. Dell,William B. Hannah's 26 research works with 563 citations and 1,609 reads, including: The global prevalence and ethnic heterogeneity of primary ciliary dyskinesia gene variants: a genetic database ...Amik Sodhi, Katherine Cox-Flaherty, Meredith Kendall Greer, Tasnim I Lat, Yuqing Gao, Deepika Polineni, Margaret A Pisani, Ghada Bourjeily, Marilyn K Glassberg, Carolyn D'Ambrosio.

Therapeutic beta-lactam dosages and broad-spectrum antibiotics are associated with reductions in microbial richness and diversity in persons with cystic fibrosis. Andrea Hahn. , Aszia Burrell ...

Fingerprint Dive into the research topics of 'Complications and Practice Variation in the Use of Peripherally Inserted Central Venous Catheters in People With Cystic Fibrosis: The Prospective Study of Peripherally Inserted Venous Catheters in People With Cystic Fibrosis Study'.

The median number of tests used by pediatric and adult clinicians, respectively, to diagnose iron deficiency were 3.5 (IQR: 1.5) and 4 (IQR: 2). Seventy-four respondents said that they had treated anemia in PwCF. Of this total, 71 (96%) had used an oral iron supplement, 26 (35%) had used intravenous iron, 22 (30%) had referred a patient for ...Dr. Deepika Polineni, MD, is an Internal Medicine specialist practicing in Kansas City, KS with 19 years of experience. This provider currently accepts 40 insurance plans including Medicaid. New patients are welcome. Hospital affiliations include …When Harry Met Sally, or When Machine Learning Met Chronic Obstructive Pulmonary DiseaseIntegrative Transcriptomic and Genomic Analysis Reveals Gene Networks Associated with Cystic Fibrosis Lung Disease Severity‪University of Kansas‬ - ‪‪Cited by 2,466‬‬ - ‪cystic fibrosis‬ - ‪lung inflammation‬ - ‪extracellular vesicles‬ - ‪primary ciliary dyskinesia‬Find great pulmonologists in De Soto, KS. View profiles with insurance information, hours and location, other patients reviews, and more.Dr. Lawrence M. Nogee is a neonatologist in Baltimore, Maryland and is affiliated with Johns Hopkins Hospital. He received his medical degree from Johns Hopkins University School of Medicine and ...HEALTH OUTCOMES ASSEMBLY: RACIAL AND ETHNIC DISPARITIES . Friday, August 27, 2021 | 9 a.m.-12:30 p.m. Presented by . KU Medical Center Office for Diversity, Equity ...

KU Medical Center was one of the sites of a phase 3 trial that led to the approval of the drug, known by its brand name, Trikafta, by the U.S. Food and Drug Administration on October 21.On August 7, 2020, Aclaris Therapeutics reported that the first patient had been dosed with ATI-450 in the company's investigator-initiated Phase 2a COVID-19 clinical trials.Deborah Friedman 1 , Beth A Smith 2 3 , Amanda Bruce 4 , Carolyn E Schwartz 5 6 , Hang Lee 7 , Hanna Pinsky 8 , Elizabeth Gootkind 8 , Margot Hardcastle 8 , Nicole Shea 2 , Christine M Roach 2 , Caitlin Miller 2 , Deepika Polineni 9 , Matthias Salathe 9 , Alexandra L Quittner 10 , Anna M Georgiopoulos 1Instagram:https://instagram. when do ku play againncaa men's bb tonightphd in nursing requirementswhat does sports teach you Background: This document presents the American Thoracic Society clinical practice guidelines for the diagnosis of primary ciliary dyskinesia (PCD). Target Audience: Clinicians investigating adult and pediatric patients for possible PCD. Methods: Systematic reviews and, when appropriate, meta-analyses were conducted to summarize all available evidence pertinent to our clinical questions. scholastic chairperson's toolkit loginaec degree Deepika Polineni, MD, MPH Associate Professor of Pediatrics, Allergy and Pulmonary Medicine Director, Cystic Fibrosis Center Washington University School of Medicine St Louis, MO : Mary Beth Scholand, MD Associate Professor in Pulmonary Medicine Director, Interstitial Lung Disease Clinic university of houston rate my professor Adam J. Shapiro1, Maureen Josephson2, Margaret Rosenfeld3, Ozge Yilmaz4, Stephanie D. Davis5, Deepika Polineni6, Elena Guadagno7, Margaret W. Leigh8 and Valery Lavergne9 1Division of Pediatric Respiratory Medicine, Montreal Children's Hospital, McGill University Health Centre Research Institute, Montreal,Disclosures. The following relevant financial relationships have been disclosed by faculty, and all have been mitigated by Pri-Med Institute. Deepika Polineni, MD, MPH: Advisor to Laurent Pharmaceuticals. Marrah Lachowicz-Scroggins, PhD: No relevant financial relationships disclosed. Charles Vega, MD, FAAFP (Moderator): Consultant to GlaxoSmithKline. Non …